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ABSTRACT
Cancer stem cells (CSCs) play an important role in tumor initiation, progression, 
therapeutic failure and tumor relapse. In this study, we evaluated the efficacy of 
the thiazole derivative 3-methylcyclopentylidene-[4-(4’-chlorophenyl)thiazol-2-yl]
hydrazone (CPTH6), a novel pCAF and Gcn5 histone acetyltransferase inhibitor, as a 
small molecule that preferentially targets lung cancer stem-like cells (LCSCs) derived 
from non-small cell lung cancer (NSCLC) patients. Notably, although CPTH6 inhibits 
the growth of both LCSC and NSCLC cell lines, LCSCs exhibit greater growth inhibition 
than established NSCLC cells. Growth inhibitory effect of CPTH6 in LCSC lines is 
primarily due to apoptosis induction. Of note, differentiated progeny of LCSC lines 
is more resistant to CPTH6 in terms of loss of cell viability and reduction of protein 
acetylation, when compared to their undifferentiated counterparts. Interestingly, in 
LCSC lines CPTH6 treatment is also associated with a reduction of stemness markers. 
By using different HAT inhibitors we provide clear evidence that inhibition of HAT 
confers a strong preferential inhibitory effect on cell viability of undifferentiated 
LCSC lines when compared to their differentiated progeny. In vivo, CPTH6 is able to 
inhibit the growth of LCSC-derived xenografts and to reduce cancer stem cell content 
in treated tumors, as evidenced by marked reduction of tumor-initiating capacity in 
limiting dilution assays. Strikingly, the ability of CPTH6 to inhibit tubulin acetylation 
is also confirmed in vivo. Overall, our studies propose histone acetyltransferase 
inhibition as an attractive target for cancer therapy of NSCLC.
INTRODUCTION
Lung cancer is the leading cause of cancer-related 
deaths. Non-small cell lung cancer (NSCLC) accounts 
for ~85% of all lung cancer cases [1]. The disease 
control achieved with classical chemotherapy doublets 
in advanced or metastatic NSCLC is usually restricted 
to only a few months [2]. Therefore, there is a need for 
development of novel agents that can be added to and 
improve the effect of traditional chemotherapy. In recent 
years, with growing insight into molecular alterations 
in lung cancer, tremendous efforts have been made to 
identify new anticancer agents. Aberrant epigenetic 
regulation is a frequent event in NSCLC, and both altered 
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DNA CpG methylation and histone post-translational 
modifications have been shown to have both predictive 
and prognostic significance in this disease [3, 4]. Thus, 
it has been recently proposed that patients with NSCLC 
might benefit from treatment with epigenetic drugs [5]. 
Histone acetyltransferase inhibitors (HATi) belong to the 
family of epigenetic drugs and represent a heterogeneous 
group of compounds able to alter histone and non-
histone protein functions [6]. Several molecules with 
HAT inhibitory activity have been identified and some of 
them showed to induce cell death preferentially in cancer 
cells when compared to normal ones [6–10]. Among 
them, the thiazole derivative 3-methyl-cyclopentylidene-
[4-(4’-chlorophenyl)thiazol-2-yl)]hydrazone (CPTH6), 
has been characterized by our group as a novel Gcn5 
and pCAF HAT inhibitor, able to activate the apoptotic 
program and to modulate the autophagic flux in a panel 
of tumor cell lines [11, 12]. Cancer stem cells (CSCs) 
have been proposed as potential culprits not only of the 
tumor initiation and progression, but also of therapeutic 
failure and tumor relapse, mainly because of their intrinsic 
resistance to conventional drugs [13]. Growing evidence 
shows a connection between epigenetic abnormalities in 
cancer and subpopulations with stem cells-like traits [14–
16]. CSCs have been identified and characterized by the 
expression of markers, including CD133, CD44, aldehyde 
dehydrogenase (ALDH), side population [17–21], and by 
their cellular traits such as morphology, colony formation 
ability, and other aggressive behaviors [22]. Nowadays, 
several studies provide strong evidence for the existence 
of a cellular subpopulation with stem-like traits also in 
NSCLC [20, 22, 23], where the presence of these cells 
predicts a worse prognosis for patients [24]. Currently, 
the development of new treatment strategies that target 
CSCs, as well as the identification of new druggable 
pathways, are the main goals of anti-cancer therapy [25–
34]. Commercially available established cancer cell lines 
cannot account for the genetic diversity among patients 
or for the heterogeneity of tumor cells. Novel approaches 
directed at eradicating CSCs could be greatly strengthened 
by the use of patient-derived CSCs as cellular model for 
the discovery of compounds that can selectively target 
these cells [35]. In this context, we investigated the 
antitumor efficacy of CPTH6 using in vitro and in vivo 
models of spheroid patient-derived lung CSCs (LCSCs).
RESULTS
CPTH6 inhibits in vitro cell viability of human 
NSCLC cell lines
To evaluate the specific functional significance 
of HAT inhibition in human NSCLC, we explored cell 
proliferation of nine commercially available established 
NSCLC cell lines exposed to increasing concentrations 
of CPTH6, a novel Gcn5 and pCAF HAT inhibitor [12]. 
Cell lines were differentially sensitive to CPTH6 treatment 
with IC50 values at 72h ranging from 65 to 205μM (73μM 
for A549, 65μM for H1299, 77μM for Calu-1, 81μM for 
A427, 85μM for Calu-3, 205μM for HCC827, 147μM for 
H460, 198μM for H1975, 83μM for H1650) (Figure 1A, 
Supplementary Figure S1A). Consistent with the HAT 
inhibitory activity of CPTH6 [12], decreased acetylation of 
both histone H3 and α-tubulin was observed in H1299 cells, 
among the most sensitive cell lines, by Western blot analysis 
after 24h treatment with CPTH6 (Figure 1B). In order to 
investigate whether CPTH6 inhibition of cell viability 
was associated with cell death in NSCLC cells, H1299 
cells were treated with CPTH6 for 24h at concentrations 
ranging from 20 to 100μM, and cell survival was assessed. 
As reported in Figure 1C, after CPTH6 exposure the 
colony formation capacity was impaired when compared to 
untreated cells in a dose-dependent fashion. In particular, 
CPTH6 at 100μM induced a significant decrease of about 
80% cell colony formation compared with untreated 
controls. Of note, at the higher concentrations reduction of 
cell viability was accompanied by the presence of Sub-G1 
peak, annexin-V binding, pro-caspase 3 activation and 
cleavage of PARP, all parameters indicative of apoptosis 
(Figure 1D, 1E, 1F, Supplementary Figure S1B). Similarly, 
CPTH6 induced apoptosis in less than 10% of A549 cells 
(Figure 1D, 1E), even when they were exposed to 5 days 
treatment with CPTH6 (data not shown).
CPTH6 inhibits in vitro cell viability of 
patient-derived lung cancer stem-like cells 
(LCSCs)
Patient-derived cancer cells, isolated from 
NSCLC surgical specimens, are undifferentiated and 
highly clonogenic cells that are resistant to conventional 
chemotherapy [21]. LCSCs, cultured in serum-free medium 
containing EGF and basic-FGF in low adherent plate, grow 
as multicellular spheroids with properties of CSCs, as 
determined by highly tumorigenicity and expression of stem 
cell markers (Supplementary Table S1). These spheroid 
LCSCs represent a suitable cellular model to search new 
therapeutic options for lung cancer and to account for the 
genetic diversity among patients, or for the heterogeneity 
of tumor cells. To this aim, spheroid LCSC lines were 
exposed to increasing concentrations of CPTH6 for 
72 h. We found that CPTH6 had a stronger and significantly 
growth-inhibitory effect in these patient-derived spheroid 
cell lines than in established NSCLC lines (Figure 2A, 
Supplementary Figure S1C), with IC50 values ranging from 
12 to 67μM (21μM for LCSC136, 23μM for LCSC36, 
12μM for LCSC18, 36μM for LCSC196, 25μM for 
LCSC223, 29μM for LCSC229, 67μM for LCSC143). Of 
note, a dose- and time-dependent reduction of cell viability 
associated with an increased percentage of cells in Sub-G1 
phase was well evident in the LCSC136 representative line 
after CPTH6 treatment (Supplementary Figure S2A, S2B).
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Figure 1: CPTH6 inhibits in vitro cell viability of human NSCLC cell lines. A. Analysis of cell viability by MTT assay in the 
indicated established NSCLC cell lines exposed to CPTH6 concentrations ranging from 10 to 100μM for 72h. B. Western Blot analysis of 
α-tubulin, histone H3, acetylated α-tubulin (Ac-Tubulin) and histone H3 (Ac-H3) levels in H1299 cells treated for 24h with CPTH6 at the 
indicated concentrations. β-actin is shown as loading and transferring control. C. Representative images and quantification of colony assay 
performed on H1299 cells untreated or treated for 24h with CPTH6 at the indicated concentrations. Percentage of clonogenicity relative of 
treated versus untreated cells is reported. D. Flow cytometric quantification of sub-G1 DNA peak by propidium iodide staining in H1299 
and A549 cells untreated or treated with CPTH6 for 72h at the indicated concentrations. E. Flow cytometric analysis of apoptotic cells by 
AnnexinV/caspase-3 staining in H1299 and A549 cells untreated or treated for 72h with CPTH6 at the indicated concentrations. Treatment 
with cisplatin (20μM) for 24h represents positive control (Pos Contr). F. Western Blot analysis of PARP cleavage in H1299 cells treated for 
72h with CPTH6 at the indicated concentrations. HSP72/73 is shown as loading and transferring control. (A) The results are reported as 
“viability of drug-treated cells/viability of untreated cells” × 100 and represent the average ± SD of three independent experiments. (B, F) 
Western Blots representative of two independent experiments with similar results are shown. (A, C, D) The results represent the average ± 
SD of three independent experiments. p-values were calculated between untreated and treated cells. #,*p<0.01.
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Figure 2: CPTH6 inhibits in vitro cell viability and self-renewal of patient-derived lung cancer stem-like cells (LCSCs). 
A. Analysis of cell viability by CellTiter-Glo assay in the indicated patient-derived LCSC lines exposed to increasing concentrations 
of CPTH6 for 72h. B, C. Flow cytometric analysis of apoptotic cells by AnnexinV/PI staining in LCSC136 cells untreated or treated 
with CPTH6 at the indicated concentrations and exposure times in presence or absence of the pan-caspases inhibitor zVAD-fmk (zVAD, 
50μM). (B) The percentage of AnnexinV+/PI- (early apoptotic cells, lower right) and AnnexinV+/PI+ (late apoptotic cells, upper right), 
cells is shown. A representative experiment out of three with similar results is shown. (C) The results represent the average ± SD of three 
independent experiments. p-values were calculated between untreated and treated cells. #,*p<0.01. D. Analysis of cell viability by CellTiter-
Glo assay in patient-derived LCSC136 line untreated or treated with CPTH6 (30μM, 72h) in presence or absence of zVAD (50μM), 
Chloroquine (CQ, 25μM) and 3-methyladenine (3-MA, 0.5mM). (A, D) The results are reported as “viability of drug-treated cells/viability 
of untreated cells” × 100. (A, D) The results represent the average ± SD of three independent experiments. p-values were calculated 
between untreated and treated cells. *p<0.01.
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To better explore the mechanism of CPTH6 
cytotoxicity in LCSCs, we quantified the amount of 
apoptotic cells after treatment. As shown in Figure 2B, 
2C, a dose- and time-dependent induction of apoptotic cell 
death by CPTH6 treatment was well evident in LCSC136 
line. In particular, the percentage of annexinV+ cells 
dose-dependently increased up to about 30% and 80% 
in LCSC136 cells treated for 72h with 30 and 50μM, 
respectively. Similar results were obtained with LCSC36 
line (data not shown). In agreement with these data, 
PARP cleavage and phosphorylation of H2AX (γH2AX ) 
were already observed after exposure of LCSC136 line 
to 30μM CPTH6 for 72h, confirming the occurrence of 
apoptosis and DNA damage, respectively, in this line 
(Supplementary Figure S2C).
The addition of the pan-caspase inhibitor zVAD-
fmk to LCSC136 line significantly diminished CPTH6-
induced annexinV+ cells compared to cells that were 
treated with CPTH6 in the absence of zVAD-fmk (Figure 
2B, 2C). Caspases inhibition, at least in part, prevented 
the cytotoxic effect of CPTH6 in LCSC136 cells, partially 
restoring the viability of cells exposed to drug (Figure 2D).
This result suggests that additional cell death 
mechanisms might be induced by CPTH6. As we 
previously reported the ability of CPTH6 to modulate 
autophagy in established tumor cell lines of different 
origin [11], we determined whether autophagy may play 
a role in CPTH6 cytotoxicity observed in LCSCs. To 
this aim, LCSCs were treated for 72h with CPTH6 in the 
presence of autophagy and apoptosis inhibitors, or with a 
combination of the two (Figure 2D). Notably, treatment of 
cells with an early (3-methyladenine) or late (chloroquine) 
stage autophagy inhibitor did not significantly affect 
CPTH6-cytotoxic effect. On the other hand, the 
simultaneous presence of autophagy and apoptosis 
inhibitors was able to block CPTH6-induced death, 
indicating that cell death occurs through mechanisms that 
involves both pathways (Figure 2D).
Next, we were interested to find out whether there 
was any synergistic or additive effect of CPTH6 when 
combined with cisplatin or pemetrexed, the current first line 
chemotherapy agents for NSCLC patients [1]. As shown in 
Supplementary Figure S2D, combined treatment (ratio 10:1) 
of low dose of CPTH6 and cisplatin or pemetrexed induced 
in LCSC136 a decreased viability compared with single 
treatment. The combination index scores were 0.6 and 0.87 
for pemetrexed/CPTH6 and cisplatin/CPTH6 respectively, 
suggesting a synergistically increased cytotoxicity of 
combined treatment compared with single ones.
CPTH6 induces the loss of CSCs expression 
markers in LCSC36 line
To evaluate the effects of CPTH6 on CSCs 
phenotype, we analyzed the change in expression levels of 
CD133 and ALDH activity in LCSC36 line, characterized 
by CD133 positivity and high ALDH activity, upon 
exposure to CPTH6. As shown in Figure 3A, 3B 24h 
of CPTH6 treatment resulted in downregulation of both 
stem cell markers in a dose-dependent manner. To test the 
functional consequences of CPTH6-induced loss of the 
CSCs expression markers, we used a tumorsphere assay 
to measure the self-renewal of CSCs [36]. Spheroids 
LCSCs were treated with CPTH6 for 24h, and the effect 
of treatment on CSCs pool was determined in a secondary 
tumorsphere assay (Figure 3C, Supplementary Figure 
S3D). Intriguingly, treatment resulted in a reduction of 
self-renewal capacity in vitro in a dose-dependent manner 
in LCSC36 and in other two LCSC lines.
To investigate whether CPTH6 results in a reduction 
of stemness properties independently of its ability 
of triggering cell death, we performed a time course 
experiment to follow change in ALDH activity upon 
CPTH6 treatment. To this aim, cells were analyzed by 
gating on forward and side scatters as well as viability to 
exclude dead cells. As shown in Figure 3D, at 72h CPTH6 
treatment was not effective in downregulating stem cell 
marker in the alive population. Next, we treated spheroid 
cultures for 24h with CPTH6 and evaluated the change in 
expression levels of CD133 and ALDH activity (Figure 
3E, 3F) and tumor spheres formation (Figure 3G) at the 
end of treatment or after 72h from CPTH6 wash out. 
After 72h of treatment withdraw, we found a significantly 
induction of ALDH-positive cells content and CD133 
expression in viable LCSCs compared to the content found 
in LCSCs directly after the treatment. Similarly, we found 
that the CPTH6-induced loss of self-renewal capacity was 
reversed at 72h of treatment withdraw. Surprisingly, no 
significant difference were observed at highest dose, likely 
for high content of apoptotic cells (about 77%) in spheroid 
cultures at this time. These data suggest that LCSCs 
disappeared from the spheroid cultures by a process of cell 
death and that CPTH6 effect on CSCs pool is reversible.
HAT inhibition preferentially affects cell viability 
of patient-derived LCSC stem counterpart
We next compared the effect of CPTH6 on the 
survival of LCSCs grown as undifferentiated multicellular 
spheroids (Stem) or as differentiated cells in adherent 
conditions (Diff). Under the latter condition, lung cancer 
spheres adhered to the plastic and acquired the typical 
morphologic features of differentiated cells and lost the 
expression of CD133, confirming the specific expression 
of this antigen in undifferentiated cells (Supplementary 
Figure S3A, S3B). As shown in Figure 4, differentiated 
progeny of both LCSC136 (Figure 4A, 4C) and LCSC36 
(Figure 4B, 4D) cells were more resistant to CPTH6 
cytotoxicity when compared to their stem counterparts. 
As expected, 72h of CPTH6 exposure increased the 
percentage of apoptotic cells in both LCSC136 and 
LCSC36 cells in a dose-dependent manner when 
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Figure 3: CPTH6 induces the loss of CSCs expression markers in LCSC36 line. A. Flow cytometric quantification of ALDH 
activity in LCSC36 cells untreated or treated with CPTH6 for 24h at the indicated concentrations. B. Flow cytometric analysis of CD133 in 
LCSC36 cells untreated (blue) or treated with CPTH6 (10μM green, 30μM grey, 50μM red) for 24h. Black line represents negative control 
(neg, no addition of primary antibody to the cells). A representative experiment out of three with similar results is shown. C. Quantification 
of tumorsphere formation of the indicated LCSC lines treated for 24h with the indicated concentrations of CPTH6. D. Flow cytometric 
quantification of ALDH activity in LCSC36 cells untreated or treated with CPTH6 at the indicated concentrations and times. E, F. Flow 
cytometric quantification of (E) ALDH activity and (F) CD133 expression in LCSC36 cells treated with the indicated concentrations of 
CPTH6 for 24h (0h) or after 72h of treatment withdraw (72h post). G. Quantification of tumorsphere formation of LCSC36 line treated as 
reported in (E, F). (C, G) Data shown represent the percentage of spheres normalized to the number of seeded cells. (A, C-G) The results 
represent the average ± SD of three independent experiments. *p<0.01. (A, C, D) p-values were calculated between untreated and treated 
cells. (E-G) p-values were calculated between 0h and 72h post.
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Figure 4: HAT inhibition preferentially affects cell viability of LCSC stem counterpart. A, B. Analysis of cell viability by 
CellTiter-Glo assay in patient-derived LCSC136 (A) and LCSC36 (B) spheroids (Stem) and their differentiated progeny (Diff) exposed to 
increasing concentrations of CPTH6 for 72h. C, D. Flow cytometric quantification of apoptotic cells by AnnexinV/PI staining in LCSC136 
(C) and LCSC36 (D) spheroid cells (Stem) and their differentiated progeny (Diff) treated for 72h with CPTH6 at the indicated concentrations. 
E. Analysis of cell viability by CellTiter-Glo assay in patient-derived LCSC136 spheroids (Stem) and their differentiated progeny (Diff) exposed 
to increasing concentrations of pan-HAT inhibitor Curcumin (Curc) for 72h. F. Analysis of cell viability by CellTiter-Glo assay in patient-
derived LCSC136 spheroids cells exposed to increasing concentrations of CPTH6, and of CPTH6-analogues MC 3080 and MC 3150 for 72h. 
(A-F) The average ± SD of three independent experiments is shown. p-values were calculated between spheroid and differentiated cells. *p<0.01
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grown as tumor spheroids, whilst less than 10% of cell 
death was observed in CPTH6-treated differentiated 
progeny. Of note, accordingly with their stemness 
features, undifferentiated LCSCs were more resistant to 
commonly used antineoplastic agents, such as cisplatin 
(DDP), when compared to their differentiated progeny, 
which were overall more sensitive to drug-induced death 
(Supplementary Figure S3C).
To further address the importance of HAT inhibition 
in LCSC survival, we analyzed the effect of both p300/
CBP HAT inhibitors Curcumin [37] and C646 [38] on 
cell viability of LCSC136 line grown as undifferentiated 
multicellular spheroids (Stem) or as differentiated in 
adherent conditions (Diff). Interestingly, both Curcumin 
(Figure 4E) and C646 (Supplementary Figure S4B) 
reduced cell viability of LCSC136 cells grown as tumor 
spheroids, whilst differentiated progeny were more 
resistant to either Curcumin or C646 induced cell death 
(Figure 4E, Supplementary Figure S4B). We next analyzed 
the activity of two CPTH6 analogues, MC 3150 and MC 
3080 (Supplementary Figure S4A, 4F), which displayed 
very poor pCAF, but a p300 HAT enzyme inhibiting 
activity higher than prototype [8]. As reported in Figure 4F 
cell viability revealed that both analogues were less potent 
than CPTH6 in terms of growth inhibition on spheroids 
LCSC136 line. Of note, both compounds only very 
slightly affected the viability of differentiated comparted 
of LCSCs (Supplementary Figure S4B). Finally, the effect 
of different HAT inhibitors on CSCs was determined in 
a secondary tumorsphere assay (Supplementary Figure 
S4C), confirming the importance of HAT enzymes in the 
self-renewal of CSCs.
CPTH6 effect on cell viability correlates, 
not only to the extent to which protein 
hypoacetylation occurs, but also to the baseline 
level of acetylated α-tubulin
Next, we tested whether CPTH6 effect on 
undifferentiated and differentiated cells may be correlated 
with baseline expression of acetylated protein. Notably, 
Western blot analysis showed that both LCSC136 and 
36 cells grown as tumor spheroids have higher level of 
acetylated α-tubulin into K40 residue when compared to 
their differentiated progeny (Figure 5A). We also observed 
that CPTH6 treatment induced a significant time- and 
dose- dependent decrease of acetylated α-tubulin and 
histone H3 in stem LCSC136 cells. In particular, we 
observed a decrease of about 45% and 85% of histone 
H3 and α-tubulin acetylation, respectively upon 24h of 
treatment with 50μM CPTH6 (Figure 5B). On the contrary, 
the differentiated progeny was more resistant to reduction 
of protein acetylation, in fact the higher concentration 
of CPTH6 50μM induced a reduction of about 2% and 
35% in the level of acetylated tubulin and of about 23% 
and 35% in the level of acetylated histone H3 after 48h 
and 72h, respectively (Figure 5C). These results suggest 
that CPTH6 effect on sensitive cells may be predicted by 
baseline level of acetylated α-tubulin. Hence, in order to 
investigate whether baseline levels of acetylated α-tubulin 
could be related to sensitivity to CPTH6, intracellular 
baseline levels of acetylated α-tubulin were quantified 
in LCSC (n=6) and NSCLC (n=8) lines. As reported 
by Western blot analysis, α-tubulin was prominently 
acetylated in 4 out of 6 LCSC lines which are consistently 
more sensitive to the growth-inhibitory effects of CPTH6 
(Figure 5D, 5E). Such observation raises the interesting 
possibility that acetylated α-tubulin might represent a 
novel marker of sensitivity to HAT inhibition.
CPTH6 reduces the in vivo growth of LCSCs-
derived tumor xenografts
We next evaluated the effect of CPTH6 on in vivo 
tumor growth of patient-derived LCSC136 cell line. We 
have previously demonstrated the high bioavailability 
of CPTH6 [12], moreover daily treatment with CPTH6 
did not produce any adverse health effects as monitored 
by diet consumption, body weight loss, toxic death and 
postural and behavioral changes in mice. To determine 
the in vivo antitumor efficacy of CPTH6, LCSC136 
spheroids cells were injected subcutaneously into 
immunocompromised (NOD/SCID) mice. As showed 
in Figure 6A, 6B and according to in vitro data, CPTH6 
treatment strongly reduced tumor growth in LCSC136 
xenografts. We next evaluated by immunohistochemical 
analysis of tumor tissues, the impact of CPTH6 treatment 
on cell proliferation (Ki67), apoptosis (TUNEL) and DNA 
damage (γH2AX ) (Figure 6C). Decreased proliferation 
and enhanced apoptosis were observed in treated group, 
in particular, the proliferation was 21.6% in the untreated 
group versus 8.8% in the treated one, and apoptotic index 
increased from 3.65% in the untreated group to 35.5% in 
the treated one, indicating that CPTH6 had a strong anti-
proliferation and apoptosis-inducing effects (p<0.05). 
LCSC136 xenografts also displayed increased γH2AX 
labeling, confirming a drug-induced DNA damage 
response in tumor specimens. We also analyzed the effect 
of CPTH6 on protein acetylation in tumor specimens 
recovered after 3 weeks of in vivo treatment. Accordingly 
to our in vitro results, we confirmed the ability of CPTH6 
to inhibit α-tubulin acetylation also in vivo (Figure 6D). 
Cellular lysates from CPTH6-treated tumors displayed a 
reduction of α-tubulin acetylation levels when compared 
to that of untreated tumors, thus confirming IHC results 
and linking the acetyltransferase inhibition activity to the 
antitumor activity in xenografts (Figure 6E).
To gain more insights into the ability of CPTH6 
to target LCSCs in vivo, we decided to perform 
immunohistochemical and Western Blot analyses for 
the CSC marker Nanog which is well expressed in this 
LCSC136 line. We found only a slight difference in 
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Figure 5: CPTH6 effect correlates, not only to the extent to which protein hypoacetylation occurs, but also to baseline 
level of acetylated α-tubulin. A. Western Blot (left panel) and relative densitometric analyses (right panel) of α-tubulin and acetylated 
α-tubulin (Ac-Tubulin) in LCSC136 and LCSC36 lines grown as spheroid cells (Stem) or in adherent conditions (Diff). B, C. Western Blot 
(left panel) and relative densitometric (right panel) analyses of α-tubulin, histone H3, acetylated α-tubulin (Ac-Tubulin) and histone H3 (Ac-
H3) levels in LCSC136 spheroid (B) and LCSC136 differentiated (C) cells treated with CPTH6 at the indicated concentrations and times. 
Protein levels were quantified by densitometric analyses and ratio between protein of interest and loading control is presented. D. Western Blot 
analysis of α-tubulin and acetylated α-tubulin (Ac-Tubulin) in the indicated established NSCLC and patient-derived LCSC lines. E. Correlation 
between acetylated α-tubulin level (high, low) and CPTH6 sensitivity (IC50 values) by Mann-Whitney test in NSCLC and patient-derived 
LCSC cells. The y-axis shows the CPTH6 concentration causing a 50% inhibition of cell viability (IC50). p value is 0.007. (A-D) β-actin is 
shown as loading and transferring control. Western blots representative of two independent experiments with similar results are shown.
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Figure 6: CPTH6 reduces the in vivo growth of LCSCs-derived tumor xenografts. A, B. Analysis of in vivo tumor growth in 
NOD/SCID mice inoculated subcutaneously with 2.5×105 LCSC136 cells and treated i.p. with CPTH6 (50mg/Kg; 5 days every 24h for 3 
weeks). C, D. Representative images of immunohistochemical detection of (C) apoptosis by TUNEL assay, proliferation by Ki67 staining, 
DNA damage by γH2AX protein staining and Nanog protein expression (D) and acetylated α-tubulin  (Ac-Tubulin) level in LCSC136-
derived tumors from untreated or treated mice with CPTH6 as reported in (A). Magnification 200×. Scale bar, 100μm. E. Western Blot 
analysis of α-tubulin and Nanog proteins expression and acetylated α-tubulin (Ac-Tubulin) level in LCSC136-derived tumors lysates 
from untreated or treated mice with CPTH6 as reported in (A). HSP72/73 is shown as loading and transferring control. Western blots 
representative of two independent experiments with similar results are shown. (B) The average ± SD of two independent experiments is 
shown. p-values were calculated between untreated and treated tumors. *p<0.01.
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the number of Nanog-positive cells in CPTH6-treated 
xenografts when compared to untreated xenografts. 
Nevertheless, Nanog-positive cells in CPTH6-treated 
samples but not in untreated ones, were often associated 
to the presence of apoptotic bodies, thus suggesting that 
treatment induces LCSCs death in vivo. We subsequently 
determined whether similar preferential targeting of 
CSCs occurs also in vivo, by analyzing tumor-initiating 
frequency (TIF) in a limiting dilution assay. To this aim 
after two weeks of treatment, cells dissociated from 
either CPTH6- or vehicle-treated tumors were injected 
into NOD/SCID mice in limiting dilution to evaluate 
the tumor forming ability (Table 1). Of note, cells from 
CPTH6-treated tumors displayed a 5-fold reduction of 
TIF, confirming reduction of CSCs in tumors by CPTH6 
treatment.
DISCUSSION
Several epigenetic inhibitors have been developed 
and shown to induce differentiation, growth arrest, or 
apoptosis in tumor cells [7–10, 39–41]. Among them, we 
previously characterized the thiazole derivative CPTH6, as 
a novel HAT inhibitor that activates the apoptotic program 
and modulates the autophagic flux in human tumor cell 
lines [11, 12].
Targeting CSCs to suppress tumor growth is a 
major focus in current cancer research [26, 28–31, 33, 35, 
42–45]. To investigate the functional significance of HAT 
inhibition in NSCLC and in targeting CSCs, in this study 
we used a panel of well-characterized established NSCLC 
and spheroid patient-derived LCSC lines. The latters 
display several stem cell-associated properties including 
self-renewal capability, higher clonogenic potential, 
resistance to chemotherapy and the expression of diverse 
CSCs markers, such as CD133, ALDH1 (detected as 
ALDH activity), Nanog and CD44. Noteworthy, none of 
analyzed markers showed a high and consistent expression 
in all the spheroids patient-derived LCSC lines, that were 
used in this study, thus confirming the heterogeneity in 
lung CSCs marker expression [46–48]. Our results show 
that CPTH6 preferentially inhibits cell viability and 
activates the apoptotic program of spheroid LCSCs with 
properties of CSCs. Interestingly, CPTH6 treatment is 
more efficient in LCSCs than in NSCLC commercially 
available cell lines. Unlike LCSC models, in which 
CPTH6 treatment induces apoptosis even at low doses, in 
established NSCLC lines CPTH6 triggers a low percentage 
of apoptotic cells only when high concentrations and time 
of exposure are used.
CPTH6 induces in spheroid LCSCs a form of 
cell death that resembles canonical caspases-dependent 
apoptosis associated with DNA damage as documented 
by appearance of Sub-G1 peak, annexin-V binding, 
PARP cleavage, and increased of H2AX phosphorylation. 
Conceivably, the effect of CPTH6 on DNA damage may 
be due to its ability to block not only H3 acetylation 
but also other histone acetylation marks, such as K16 
acetylation of H4 histone, that promotes double-strand 
breaks repair [49] or to influence non-histone acetylated 
proteins that are involved in DNA damage and repair 
such as p53, ATM, Ku70 and Exo1 [50]. Noteworthy, 
single-agent antitumor activity was observed in spheroid 
LCSC-derived models treated with CPTH6, without signs 
of toxicity as evidenced by body weight measurement, 
diet consumption, toxic death and postural and behavioral 
changes of mice. CPTH6 treatment reduced the growth 
of LCSC-derived tumors and significantly increased the 
amount of apoptotic and DNA damaged cells present in 
the xenografts. By contrast, CPTH6 treatment had only 
a moderate not significant inhibitory effect and did not 
induce apoptosis in H1299 xenografts (data not shown). 
Notably, the preferential targeting of lung population with 
CSC properties by CPTH6 is also underscored by the 
evidence that its anti-tumor effect is accompanied in vivo 
by a decrease in stem cell markers, as Nanog. Moreover, 
Nanog-positive cells in CPTH6-treated samples but not 
in untreated one, were often associated to the presence of 
apoptotic bodies, thus suggesting the treatment induces 
selectively LCSCs death. CPTH6 also preferentially 
reduced the proportion of cells with self-renewal potential 
as measured by secondary tumorsphere assays and by 
tumor-initiating capability following limiting dilution 
re-implantation of cells into secondary immunodeficient 
mice. By using different HAT inhibitors, we also 
provide clear evidence that inhibition of HAT confers 
a strong preferential inhibitory effect on cell viability 
of undifferentiated LCSC lines when compared to their 
Table 1: In vivo limiting diluition assay showing that CPTH6 reduced tumor-initiating capability of LCSC136
Cells (n) Untreated CPTH6
250000 9(8) 9(3)
50000 9(3) 9(1)
TIF 1/118000 1/570000
P=0.00532
Cells dissociated from LCSC 136 tumors were re-implanted in limiting dilutions into flank of NOD/SCID 
immunodeficient mice. The number of mice that grew tumors at week 8 out of total of 9 mice per group (in parenthesis) is 
tabulated. Tumor Initiating formation (TIF) was calculated using the ELDA software.
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differentiated progeny. Of note, two compounds closely 
related to CPTH6 which displayed higher p300 and very 
poor pCAF inhibiting activity [8], and the specific p300 
inhibitor C646, were less/comparably potent than CPTH6 
in terms of growth inhibition on spheroids but very slightly 
affected the viability of differentiated LCSC.
Our results are also in agreement with papers 
reporting that epigenetic modulation, using chromatin 
modifiers, appears as an encouraging means to control 
CSCs fate [51, 52]. In this context, a dual role of 
histone acetylation in embryonic stem cell pluripotency 
maintenance and differentiation [24], as well as the ability 
of several epigenetic compounds to modulate stem cells 
and tumor cell differentiation, has been shown [53, 54]. 
CPTH6 effect on cell viability seems to be correlated 
not only to the extent to which protein hypoacetylation 
occurs but also to baseline level of acetylated α-tubulin, 
which was particularly prominent in sensitive LCSCs. 
LCSC lines are more sensitive than established NSCLC 
cells not only in terms of loss of cell viability, but also in 
the decreasing of proteins acetylation. In fact, a different 
response in decreasing of their acetylation level of H3 
histone and α-tubulin after CPTH6 treatment was observed 
in undifferentiated LCSC lines when compared to their 
differentiated progeny. Of note, differentiated progeny of 
LCSC lines have lower level of expression of acetylated 
α-tubulin when compared to relative LCSCs grown as 
multicellular spheroids.
Acetylated tubulin is implicated in a broad range of 
cell functions including intracellular endoplasmic reticulum 
(ER) localization and ER-mitochondria interactions [55] 
as well as the regulation of microtubule dynamics [56]. 
Recently, high level of acetylated tubulin expression 
have been found correlated with a higher tumor grade in 
squamous cell carcinoma of the head and neck [57], and 
its expression has been suggested as a prognostic marker 
in epithelial malignancies and as a marker for sensitivity 
to chemotherapy [58]. A relationship between high level 
of α-tubulin acetylation and metastatic behaviour of basal-
like breast cancers, it has been also recently reported [59]. 
Hence, level of α-tubulin acetylation may represent a 
reliable biomarker for predicting response to HATi treatment 
to identify patients likely to benefit from these drugs. 
Strikingly, the ability of CPTH6 to inhibit tubulin acetylation 
was confirmed also in vivo. Even if further studies should be 
performed to fully address the possibility that the effects on 
tubulin acetylation could be responsible for the apoptosis 
and tumor growth inhibition, emerging data support a 
role for tubulin in the execution of cell death in response 
to stress. In particular, tubulin has been demonstrated 
to interact with regulators of mitochondrial membrane 
permeability and apoptosis [60]. Tubulin acetylation occurs 
on lysine 40 (K40) by the α-tubulin acetyltransferase 1 
(ATAT1, [61]) an acetyltransferase belonging to the Gcn5 
HAT family. Our results showing that α-tubulin levels 
correlate with drug sensitivity enforce the evidence that 
ATAT1 could be another direct target of CPTH6 and that 
level of acetylated tubulin may be a predictive biomarker of 
response to this class of HAT inhibitors.
Indeed, we cannot exclude that tubulin acetylation 
status may be a new marker for CSCs. Additional studies 
using a larger number of patient-derived cells with stem 
cells features are necessary to determine the significance 
of α-tubulin acetylation as a CSCs marker.
Overall, we demonstrated CPTH6 antitumor activity 
in both stem and non-stem cell populations, thus the 
proposed approach may represent a potentially successful 
therapeutic strategy from both a classical hierarchical 
static model of CSCs point of view and a dynamic 
stemness perspective.
MATERIALS AND METHODS
Cell culture and reagents
Human commercially available established NSCLC 
lines (H1299, H460, A549, H1650, Calu-1, Calu-3, A427, 
H1975, HCC827) were cultured in 10% inactivated 
fetal bovine serum (HyClone, Thermoscientific, South 
Logan, UT) in RPMI medium (EUROCLONE, Milan, 
IT). LCSC18, LCSC36, LCSC136, LCSC196, LCSC223, 
LCSC229, LCSC143 lines were isolated from lung 
patients, and cultured as spheroid cultures in CSCs 
medium [21, 62]. LCSCs differentiation was obtained by 
growing cells in adherent conditions for 24h in DMEM 
10% plus fetal bovine serum (HyClone, ThermoScientific) 
and for 3 additional days in Bronchial Epithelial Cell 
Growth Medium (Cambrex, East Rutherford, NJ, 
USA). 3-Methylcyclopentylidene-[4-(4’-chlorophenyl)
thiazol-2-yl]hydrazone (CPTH6) was dissolved in 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, 
MO, USA) and diluted to the final concentrations in 
complete medium. For all the experiments cells were 
treated with 1% DMSO, as control. After 24h from 
seeding, exponentially growing cells were treated with 
CPTH6 at concentrations ranging from 1 to 100μM  for 
24-120h. zVAD-fmk (zVAD, 50μM, Sigma-Aldrich), 
3-methyladenine (3-MA, 0.5mM, Sigma-Aldrich) and 
chloroquine (CQ, 25μM, Sigma-Aldrich) were dissolved 
in DMSO.
Cell viability, clonogenic and tumorsphere 
formation assays
The inhibitory effect of CPTH6 on i) NSCLC cell 
growth by measuring 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide inner salt (MTT, Sigma-
Aldrich) dye absorbance of cells, and ii) spheroids 
LCSCs cell growth by quantitation of the ATP present 
in metabolically active cells using CellTiter-Glo® 
Luminescent (Promega, Fitchburg, Wisconsin, USA). 
Manifacturer’s protocol was followed. To evaluate the 
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cell colony-forming ability, cell suspensions from different 
samples were seeded into 60-mm Petri dishes for 10 days. 
Colonies were stained with 2% methylene blue in 95% 
ethanol and counted (1 colony>50 cells). The surviving 
fractions were calculated as the ratio of absolute survival 
of the treated sample/survival of untreated control sample. 
For combination treatment, cells were treated with each 
drug, either alone or in combination, as follows: (a) 
CPTH6 (b) Pemetrexed or cisplatin (c) Pemetrexed or 
cisplatin followed by CPTH6. Data were analyzed by 
the median-effect method (CalcuSyn software, Biosoft) 
to determine the combination index (CI) [62]. For 
tumorsphere assay, spheroid cultures were recovered 
after treatment, counted and seeded in 24-well ultra low-
attachment surface plates at a density of 5×102 cells/
well and cultured as previously described. After 10 days, 
spheres were photographated and counted. Data shown 
represent the percentage of spheres normalized to the 
number of seeded cells.
Flow cytometric analysis
Cell cycle distribution by PI staining and apoptosis 
by AnnexinV-FITC (BD biosciences, San Diego, CA, 
USA)/PI staining were performed as previously described 
[62]. For analysis of CD133+ subpopulation, the cells 
were washed with PBS, and then incubated with antibody 
against CD133/1 conjugated with phycoerythrin (PE; 
MiltenyiBiotec, BergischGladbach, Germany) on ice 
in the dark for 20 min. After the cells had been washed 
with PBS, the CD133+ and CD133− populations were 
analyzed by FACS. Active caspase-3 Apoptosis Kit (BD 
biosciences) was used to detect the heterodimer of 17 and 
12 kDa subunits, which is derived from the pro-enzyme. 
For annexinV and caspase-3 double staining, cells were 
washed with 1× binding buffer and then incubated 
with FITC annexinV (BD biosciences ) for 15 min at 
room temperature in the dark. After annexinV staining, 
caspase-3-PE staining was performed on the same cells 
following manufacturer instructions. ALDH activity was 
evaluated by ALDEFLUOR kit (ALDH, STEMCELL 
Tecnologies, Vancouver, BC, Canada) following 
manufacturer instructions. All flow cytometric analyses 
were performed by using BD Accuri™ C6 flow cytometer 
(BD biosciences).
Western blot analysis
Western blot analyses of total protein extracts were 
performed as previously described [12]. Immunodetection 
was performed using antibodies directed to: H3 histone 
(abcam), H3 acetylated histone (Millipore, Billerica, MA, 
USA), α-tubulin (DM1A) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), acetyl-α-tubulin (K40) (Sigma-
Aldrich), γH2AX (Ser139) (Millipore), PARP cleaved 
(Millipore), PARP (Santa Cruz Biotechnology) β-actin 
(Sigma-Aldrich), HSP72/73 (Calbiochem, San Diego, 
CA, USA), anti-mouse or anti-rabbit immunoglobulin 
G (IgG)-horseradish peroxidase conjugated antibodies 
(Cell Signaling; Amersham Biosciences, Freiburg, 
Germany). Antibody binding was visualized by enhanced 
chemiluminescence method (Amersham Biosciences) 
according to manufacturer’s specification and recorded 
on autoradiographic film (Amersham Biosciences). 
Densitometric evaluation was performed using Image J 
software and normalized with relative controls depending 
on the Analysis.
In vivo experiments
All procedures involving animals and their care 
were authorized and certified by the decree n. 67/97A of 
the Italian Minister of Health and protocol 2560/97 of the 
Rome Health Service Unit (ASL – RMB)
For in vivo experiments, CPTH6 was dissolved in 
Carboxymethyl cellulose (Sigma, C9481). To evaluate 
the effect of CPTH6 on tumor growth, 2.5×105 LCSC136 
cells were resuspended in 200 μl of matrigel (2.5mg/ml, 
BD Biosciences, 354234) and injected subcutaneously 
into 6-8 week-old female immunocompromised (NOD/
SCID) mice (10 for each group). For H1299 xenografts, 
5×106 cells were injected intramuscularly into 6-8 
week-old female immunodeficient athymic nude (nu/
nu) mice (10 for each group). Intraperitoneal treatment 
with CPTH6 (50 or 100mg/Kg) every 24h started when 
tumors were palpable (about 20 and 80 days after cell 
injection for H1299 and for LCSC136 respectively), and 
stopped after three weeks. Mice survival was calculated by 
euthanizing the animals when the tumors reached 2.0 gr. 
The experiments were repeated twice. Immediately after 
sacrifice the formed tumors were removed and cut in two. 
One half was frozen in liquid nitrogen and stored at −80C 
for Western blot analysis, and one half was fixed in 4% 
buffered formalin and routinely paraffin embedded for 
Immunohistochemistry analysis.
For the limiting dilution assay, cells dissociated 
from xenograft tumors were admixed with Matrigel and 
subcutaneously injected in limiting dilutions into NOD/
SCID mice to evaluate the tumor forming. Tumor-
initiating frequency (TIF) was calculated using the ELDA 
Software [63].
Immunohistochemistry (IHC) and In vivo 
Terminal DeoxynucleotidylTransferase-Mediated 
Nick End Labeling (TUNEL) assay
Phosphorylated form of H2AX, α-tubulin 
acetylation, Ki-67 and Nanog expression were 
evaluated, by IHC on paraffin embedded sections cut 
from tumor xenografts, using the following antibodies: 
γH2AX(Ser139, Millipore), Ki-67 (MIB-1, Dako, 
Milan, Italy), Nanog (Cell Signaling), acetyl-α-tubulin 
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(K40) (Sigma-Aldrich). For each tumor, three different 
5μm paraffin sections were analyzed and examined 
by light microscopy. Sections were scanned at 200× 
magnification. H2AX and Ki-67 nuclear immunoreaction 
of tumor cells was counted in four high-power fields 
(400× magnification) per section. For each tumor, counts 
were averaged to determine the number of positive 
cells. Immunoreactions were revealed by a streptavidin-
biotin enhanced immunoperoxidase technique in an 
automated autostainer (BondTM Max, Leica BioSystem). 
The immunohistochemical detection of apoptosis was 
performed by TUNEL assay using a commercial kit 
(In Situ Cell Death Detection Kit, POD, Roche). The 
assay was performed according to the manufacturer’s 
instructions. For each tumor, three different 5μm frozen 
sections were analyzed and examined by light microscopy. 
Sections were scanned at 200× magnification. Apoptosis 
of tumor cells was counted in four high-power fields (400× 
magnification) per section. Evaluation of the IHC results 
was performed independently and in blinded manner by 
two investigators.
Statistics
Experiments were replicated three times, unless 
otherwise indicated, and the data were expressed as 
average ± standard deviation (SD). Differences between 
groups were analyzed with a two-sided paired or 
unpaired t test and were considered to be statistically 
significant for p<0.05. Mann-Whitney test were used for 
correlation studies.
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